EMBO molecular medicine
Correction to: De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.
Duo Xu, Yanyun Gao, Shengchen Liu, Shiyuan Yin, Tong Hu, Haibin Deng, Tuo Zhang, Balazs Hegedüs, Thomas M Marti, Patrick Dorn, Shun-Qing Liang, Ralph A Schmid, Ren-Wang Peng, Yongqian Shu
Published: 202610.1038/s44321-025-00366-5
No abstract available for this study.